Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 04:00PM ET
6.62
Dollar change
+0.11
Percentage change
1.69
%
IndexRUT P/E- EPS (ttm)-0.85 Insider Own44.53% Shs Outstand56.62M Perf Week10.52%
Market Cap374.83M Forward P/E- EPS next Y-1.21 Insider Trans-3.13% Shs Float31.41M Perf Month13.55%
Income-47.78M PEG- EPS next Q-0.27 Inst Own41.80% Short Float8.57% Perf Quarter26.82%
Sales0.00M P/S- EPS this Y24.37% Inst Trans-0.37% Short Ratio11.08 Perf Half Y64.27%
Book/sh4.46 P/B1.48 EPS next Y-34.81% ROA-17.02% Short Interest2.69M Perf Year172.43%
Cash/sh4.49 P/C1.48 EPS next 5Y- ROE-17.78% 52W Range2.24 - 7.77 Perf YTD149.81%
Dividend Est.- P/FCF- EPS past 5Y-138.68% ROI-18.80% 52W High-14.80% Beta1.86
Dividend TTM- Quick Ratio34.61 Sales past 5Y0.00% Gross Margin- 52W Low194.88% ATR (14)0.44
Dividend Ex-Date- Current Ratio34.61 EPS Y/Y TTM34.59% Oper. Margin- RSI (14)60.07 Volatility6.40% 8.67%
Employees124 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom2.33 Target Price7.00
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q18.33% Payout- Rel Volume0.62 Prev Close6.51
Sales Surprise- EPS Surprise5.47% Sales Q/Q- EarningsNov 07 AMC Avg Volume243.05K Price6.62
SMA208.29% SMA5016.78% SMA20047.24% Trades Volume150,711 Change1.69%
Date Action Analyst Rating Change Price Target Change
May-07-24Upgrade Piper Sandler Neutral → Overweight $6 → $12
Nov-14-23Downgrade Piper Sandler Overweight → Neutral $42 → $6
Aug-15-23Downgrade Wedbush Outperform → Neutral $19 → $6
Aug-15-23Downgrade SVB Securities Outperform → Market Perform $6
Aug-15-23Downgrade RBC Capital Mkts Outperform → Sector Perform $23 → $7
May-04-23Upgrade Goldman Sell → Neutral $6
Jun-10-22Initiated Wedbush Outperform $21
May-02-22Initiated RBC Capital Mkts Outperform $30
Jan-19-22Initiated Goldman Sell $10
Apr-20-21Initiated SVB Leerink Outperform $36
Nov-13-24 08:00AM
Nov-07-24 04:01PM
Sep-10-24 08:00AM
Aug-21-24 09:55AM
Aug-05-24 08:00AM
08:50PM Loading…
May-22-24 08:50PM
May-10-24 03:36PM
May-08-24 11:55PM
04:05PM
May-07-24 07:12AM
06:30AM
Mar-20-24 10:31AM
06:58AM
Mar-19-24 08:53PM
05:33PM
04:01PM Loading…
04:01PM
Mar-12-24 06:30AM
Dec-18-23 12:00PM
Nov-14-23 07:28PM
Nov-13-23 04:05PM
Aug-15-23 03:02PM
09:59AM
02:34AM
Aug-14-23 04:05PM
04:01PM
Jun-18-23 08:03AM
May-31-23 06:30AM
May-09-23 04:05PM
May-08-23 06:05AM
Apr-24-23 06:30AM
09:55AM Loading…
Apr-11-23 09:55AM
Apr-04-23 02:47PM
Mar-14-23 04:05PM
Mar-09-23 06:33AM
Feb-08-23 06:30AM
Dec-21-22 06:46AM
Dec-14-22 05:15AM
Dec-07-22 04:01PM
Nov-28-22 10:37AM
Nov-03-22 04:05PM
Oct-17-22 04:05PM
Sep-22-22 06:30AM
Aug-08-22 04:05PM
Aug-03-22 06:30AM
Jun-21-22 09:57AM
Jun-01-22 06:30AM
May-09-22 04:05PM
Mar-30-22 06:30AM
Mar-23-22 02:53PM
Mar-10-22 04:02PM
Mar-09-22 06:30AM
Feb-28-22 04:05PM
Feb-10-22 06:30AM
Feb-01-22 04:05PM
Jan-19-22 12:51PM
Dec-23-21 05:00AM
Nov-09-21 04:05PM
Sep-24-21 07:55AM
Sep-08-21 06:30AM
Sep-03-21 07:33AM
Aug-09-21 04:05PM
Jun-26-21 04:30AM
Jun-07-21 04:10PM
04:05PM
May-10-21 04:05PM
Mar-30-21 04:05PM
Mar-25-21 11:56PM
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
William ArsaniDirectorAug 09 '24Sale4.25814,8743,463,2140Aug 12 04:30 PM
Logos SPV 1 LPDirectorAug 09 '24Proposed Sale4.24814,8743,455,066Aug 09 04:20 PM
Schmid John P.DirectorMar 25 '24Buy3.7417,80966,60626,965Mar 25 07:10 PM
Schmid John P.DirectorMar 22 '24Buy3.629,15633,1339,156Mar 25 07:10 PM
Berger Heather A.DirectorMar 25 '24Buy3.741,3004,8661,300Mar 25 07:09 PM